Maravai LifeSciences Holdings, Inc. reported second quarter 2026 financial results on August 6, 2026. Total revenue increased 8.5% year-over-year to $51.4 million, driven by an 11.5% rise in TriLink segment sales and a 2.8% increase in Cygnus segment sales. The company reported a net loss of $(21.6) million and positive Adjusted EBITDA of $8.7 million for the quarter. Management raised full-year 2026 Adjusted EBITDA guidance to $33 million–$35 million, up from the previous range of $30 million–$32 million, while reiterating revenue guidance of $205 million–$215 million. Maravai LifeSciences operates in the life sciences industry, providing reagents and services to researchers and biotech innovators.